HighVista Strategies LLC Has $1.47 Million Stake in Guardant Health, Inc. $GH

HighVista Strategies LLC reduced its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 45.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,265 shares of the company’s stock after selling 23,453 shares during the quarter. HighVista Strategies LLC’s holdings in Guardant Health were worth $1,471,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. IFP Advisors Inc grew its holdings in Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares during the period. Signaturefd LLC raised its holdings in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the period. Allworth Financial LP boosted its position in shares of Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Guardant Health in the 2nd quarter valued at $62,000. Finally, SVB Wealth LLC bought a new stake in shares of Guardant Health in the 1st quarter valued at $54,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In related news, insider Terilyn J. Monroe sold 55,167 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the transaction, the insider directly owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. This trade represents a 72.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Brian Bell sold 80,362 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the sale, the chief financial officer directly owned 28,052 shares in the company, valued at $2,893,283.28. This trade represents a 74.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 332,838 shares of company stock valued at $34,651,875. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on GH shares. TD Cowen lifted their target price on Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Citigroup reissued a “buy” rating on shares of Guardant Health in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. BTIG Research increased their price objective on shares of Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Guggenheim boosted their price objective on shares of Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Twenty-three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.86.

Guardant Health Trading Down 0.6%

Shares of GH stock opened at $102.62 on Thursday. The firm’s fifty day moving average price is $87.13 and its two-hundred day moving average price is $64.63. Guardant Health, Inc. has a 1 year low of $29.91 and a 1 year high of $112.43. The firm has a market capitalization of $12.93 billion, a P/E ratio of -31.97 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period in the prior year, the firm posted ($0.88) earnings per share. The business’s revenue for the quarter was up 38.5% compared to the same quarter last year. As a group, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.